Journal of Managed Care & Specialty Pharmacy

Article	Citations
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia	62
Correction	58
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis	47
What is needed to sustain comprehensive medication management? One health plan’s perspectives	35
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data	28
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy	26
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues	19
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review	19
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments	18
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance	17
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder	15
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness	14
The effect of early initiation of aripiprazole once-monthly 400 mg on health care resource utilization and health care costs in patients diagnosed with bipolar I disorder: Real-world evidence from US	13
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	13
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States	12
Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey	12
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative	12
Real-world evidence: A new era is upon us	12
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria	11
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program	11
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B	11
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer	11
Real-world primary nonadherence to antiobesity medications	11
Evaluating the burden of illness of metabolic dysfunction–associated steatohepatitis in a large managed care population: The ETHEREAL Study	10
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease	10

Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study	10
Poster Abstracts - Academy of Managed Care Pharmacy 2024	10
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol	10
Introducing the Managed Care Pharmacy Primer Series	9
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer	9
Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines	9
Place of care and costs associated with acute episodes and remission in schizophrenia	9
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population	8
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	8
AMCP Format for Formulary Submissions 5.0	8
Impact of telehealth on hydroxyurea adherence and clinical outcomes in sickle cell disease management: A systematic review and meta-analysis	8
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system	8
Laboratory monitoring to reduce adverse drug-related events: a mixed methods study	8
Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin	8
Evolution of the Military Health System compounded drugs utilization and management	8
Assessing the impact of a financial incentive and refill reminder program on medication adherence and costs	8
Social determinants of health and adult influenza vaccination: a nationwide claims analysis	8
From access to equity: The devil is in “Z” details	7
Correction	7
Trends in opioid prescribing by oncologists for Medicare beneficiaries from 2014 to 2022	7
Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States	7
Antidepressant adherence using group-based trajectory modeling among postpartum women with Texas Medicaid	7
Trends in delivery of comprehensive medication reviews by race and ethnicity, 2013-2021	7
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States	7
Employee retention for subscribers with and without an obesity diagnosis in self-insured employer health plans: A claims-based analysis	7
Addressing gaps to strengthen patient-centricity in formulary decision-making: An example applied to Colorado’s prescription drug affordability board implementation	7
Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis	6
Infusion therapy patient outcomes are similar at reduced costs in alternative sites of care compared with hospital outpatient departments: A matched cohort analysis of infusion therapy across multiple	6
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	6
AMCP Market Insights: Payer best practices in food allergy management	6
Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program	6
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	6
When are breakthrough therapies cost-effective?	6
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States	6
Resmetirom for nonalcoholic steatohepatitis	6
A dynamic analysis of medication adherence	6
Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act’s Medicare Drug Price Negotiation Program	6
Correction	6
Risk of asthma exacerbation associated with opioid and nonopioid analgesic use in children with current asthma	6
Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs	6
Cost sharing in managed care and the ethical question of business purpose	6
Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States	6
The association of direct-acting antiviral therapy with health care utilization and costs in patients with chronic hepatitis C virus infection: A systematic review of real-world studies in the United	6
Poster Abstracts - Academy of Managed Care Pharmacy 2025	6
The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population	6
Characterizing Medicare Medication Therapy Management program enrollees with central nervous system–active polypharmacy	6
AMCP Market Insights: Impact of the evolving understanding of multiple sclerosis and emerging treatment approaches on managed care	6
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder	6
Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review	6
Nonfederal average manufacturer price to estimate savings generated by minimum discounts under the Inflation Reduction Act	6

First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eli	6
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States	6
Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis	6
Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste	5
Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives	5
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it	5
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanoma	5
AMCP Partnership Forum: Racial health disparities—a closer look at benefit design	5
Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study	5
Health care resource utilization and costs among patients with spasticity or cervical dystonia	5
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States	5
Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions	5
The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review	5
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	5
Oral treatments for outpatient COVID-19: Effectiveness and value	5
Treatment patterns, health care resource utilization, and costs of heavily treatment-experienced people with HIV in the United States	5
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis	5
Payer perceptions on the use of patient-reported outcomes in oncology decision making	5
The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah	5
Burden of hospitalization for heart failure in the United States: a systematic literature review	5
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value	5
Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey	5
Limited utility of price transparency data for drugs	5
Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis	5
Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy	5
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States	5
Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement	5
The economic burden of Parkinson disease among Medicare beneficiaries	5
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	5
Health care costs and resource utilization among patients with myasthenia gravis in the United States	5
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria	5
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review	5
Advancing the conversation: 30 years of scholarship in managed care pharmacy	5
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	4
Pharmacoequity measurement framework: A tool to reduce health disparities	4
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	4
Building health plan–pharmacist provider partnerships to optimize medication outcomes	4
Associations between pharmacy choice and influenza vaccination: Mail order vs community pharmacy users	4
Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis	4
Herpes zoster vaccine uptake following provider prescription among older adults in the United States	4
Primary care physicians prescribe fewer expensive combination medications than dermatologists for acne: A retrospective review	4
Dose escalation of biologics in biologic-naive patients with Crohn’s disease: Outcomes from the ODESSA-CD study	4
Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema	4
The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018	4
Will the emerging private-label market access channel help or hinder biosimilar market access?	4
Corrections	4
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schi	4
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions	4
Characterizing health plan evidence review practices	4
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations	4
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective	4
AMCP Market Insights: Payer best practices for timely diagnosis and optimal management of idiopathic hypersomnia	4
The cost impact of disease progression to metastatic castration-sensitive prostate cancer	4
The effectiveness and value of suzetrigine for moderate to severe acute pain: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council	4
Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States	4
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States	4
Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States	4
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis	4
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs	4
Impact of copay maximizers on total patient liability among patients using specialty medicines	4
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective	4
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cance	4
A primer on copay accumulators, copay maximizers, and alternative funding programs	4
Atidarsagene autotemcel for metachromatic leukodystrophy	4
Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma	3
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analys	3
Poster Abstracts - Academy of Managed Care Pharmacy 2022	3
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States	3
The time is now: Addressing health inequities in the workforce	3
Impact of a human papillomavirus vaccination clinical program in a commercially insured population	3
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective	3
Poster Abstracts - NEXUS 2025	3
Emerging trends in pharmacy operations: Perspectives on the 2024 AMCP Foundation Survey	3
A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B	3
Correction	3
Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment	3
Evolving oncology care management trends in the United States: A survey among health care decision makers	3
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system	3
Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018	3
Unmanaged depression and chronic disease medication adherence in Medicare Advantage beneficiaries: A claims-based analysis	3

Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes	3
Unlocking the potential of digital therapeutics: The need for consistent and granular inclusion in drug compendia for managed care	3
Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028	3
Pharmacist vs physician management of e-visit requests for COVID-19 medication: A randomized clinical trial	3
Descriptive study of the real-world, long-term cost estimates and duration of use for hormonal and nonhormonal intrauterine devices using US commercial insurance claims	3
Best practices and rationale for expanding Medicaid access to continuous glucose monitoring	3
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars	3
Pharmacist-managed multistep order transmittal for electronic specialty prescriptions reduces represcribing burden in ambulatory clinics: A retrospective cohort pilot study	3
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) stu	3
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program	3
Changes in blood pressure, medication adherence, and cardiovascular-related health care use associated with the 2018 angiotensin receptor blocker recalls and drug shortages among patients with hyperte	3
Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States	3
Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US	3
Identifying potentially undiagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease: Development of a predictive algorithm using claims data	3
Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States	3
Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi	3
Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation	3
Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes	3
Addressing complexity: The development and pilot testing of a user-friendly Medicare Part D patient decision aid tool	3
Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease	3
Cost-related barriers to medication use among diverse participants with obesity-associated asthma	3
Dynamic changes in medication burden leading to fall and hospital readmissions in older adults: Toward a strategy for improving risk and managing costs	3
Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste	3
The impact of biosimilar insulins on the diabetes landscape	3
The effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa	3
Impact of a pharmacy care management service on cardiometabolic medication adherence and resource use for Medicare Advantage beneficiaries	3
HIV preexposure prophylaxis treatment patterns in a national health plan population	3
Procurement and use of social determinants of health data among key health care stakeholders	3
Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population	3
Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin	3
Health care resource utilization and costs among individuals with vs without Huntington disease in a US population	3
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension	3
Burden of illness in progressive fibrosing interstitial lung disease	3
The impact of opioid prescribing report cards in Medicaid	3
Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved popul	3
Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder	3
Telephone-based social health screening by pharmacists in the nonadherent Medicare population	3
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	3
Does the diabetes health plan have a differential impact on medication adherence among beneficiaries with fewer financial resources?	3
Marginal health care expenditures and health-related quality of life burden in patients with migraine	3
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States	3
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States	3
Marginal health care expenditures for melanoma care in the United States	3